{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:16:15Z","timestamp":1793373375842,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"crossref","award":["13GW0479B"],"award-info":[{"award-number":["13GW0479B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A reduced amyloid-\u03b2 (A\u03b2)42\/40 peptide ratio in blood plasma represents a peripheral biomarker of the cerebral amyloid pathology observed in Alzheimer\u2019s disease brains. The magnitude of the measurable effect in plasma is smaller than in cerebrospinal fluid, presumably due to dilution by A\u03b2 peptides originating from peripheral sources. We hypothesized that the observable effect in plasma can be accentuated to some extent by specifically measuring A\u03b21\u201342 and A\u03b21\u201340 instead of A\u03b2X\u201342 and A\u03b2X\u201340.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We assessed the plasma A\u03b2X\u201342\/X\u201340 and A\u03b21\u201342\/1\u201340 ratios in an idealized clinical sample by semi-automated A\u03b2 immunoprecipitation followed by closely related sandwich immunoassays. The amyloid-positive and amyloid-negative groups (dichotomized according to A\u03b242\/40 in cerebrospinal fluid) were compared regarding the median difference, mean difference, standardized effect size (Cohen\u2019s d) and receiver operating characteristic curves. For statistical evaluation, we applied bootstrapping.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median A\u03b21\u201342\/1\u201340 ratio was 20.86% lower in amyloid-positive subjects than in the amyloid-negative group, while the median A\u03b2X\u201342\/X\u201340 ratio was only 15.56% lower. The relative mean difference between amyloid-positive and amyloid-negative subjects was \u221218.34% for plasma A\u03b21\u201342\/1\u201340 compared to \u221215.50% for A\u03b2X\u201342\/X\u201340. Cohen\u2019s d was 1.73 for A\u03b21\u201342\/1\u201340 and 1.48 for plasma A\u03b2X\u201342\/X\u201340. Unadjusted p-values\u2009&lt;\u20090.05 were obtained after .\ufeff\ufeff632 bootstrapping for all three parameters. Receiver operating characteristic analysis indicated very similar areas under the curves for plasma A\u03b21\u201342\/1\u201340 and A\u03b2X\u201342\/X\u201340.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings support the hypothesis that the relatively small difference in the plasma A\u03b242\/40 ratio between subjects with and without evidence of brain amyloidosis can be accentuated by specifically measuring A\u03b21\u201342\/1\u201340 instead of A\u03b2X\u201342\/X\u201340. A simplified theoretical model explaining this observation is presented.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12987-022-00390-4","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:03:18Z","timestamp":1670036598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Is plasma amyloid-\u03b2 1\u201342\/1\u201340 a better biomarker for Alzheimer\u2019s disease than A\u03b2X\u201342\/X\u201340?"],"prefix":"10.1186","volume":"19","author":[{"given":"Hans-Wolfgang","family":"Klafki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Wirths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Esselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schuchhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"issue":"8","key":"390_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"390_CR2","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"key":"390_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1632","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1632.","journal-title":"JAMA Neurol"},{"issue":"5","key":"390_CR4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358. https:\/\/doi.org\/10.1002\/ana.25334.","journal-title":"Ann Neurol"},{"issue":"7","key":"390_CR5","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","volume":"98","author":"Y Li","year":"2022","unstructured":"Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, et al. Validation of plasma amyloid-beta 42\/40 for detecting Alzheimer disease amyloid plaques. Neurology. 2022;98(7):e688\u201399. https:\/\/doi.org\/10.1212\/WNL.0000000000013211.","journal-title":"Neurology"},{"issue":"3","key":"390_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma p-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1.","journal-title":"Nat Med"},{"issue":"5","key":"390_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"8","key":"390_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381. https:\/\/doi.org\/10.1001\/jama.2020.12134.","journal-title":"JAMA"},{"issue":"3","key":"390_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2.","journal-title":"Nat Med"},{"issue":"5","key":"390_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","journal-title":"Acta Neuropathol"},{"key":"390_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac333","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Bali D, Ashton NJ, Barthelemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2022. https:\/\/doi.org\/10.1093\/brain\/awac333.","journal-title":"Brain"},{"key":"390_CR12","unstructured":"Alzforum. 2022 Plasma A\u03b2 Test Wins Approval\u2014Are p-Tau Tests Far Behind? 24 Nov. 2020. Retrieved 03 March, 2022. https:\/\/www.alzforum.org\/news\/research-news\/plasma-av-test-wins-approval-are-p-tau-tests-far-behind."},{"key":"390_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","volume":"519","author":"KM Kirmess","year":"2021","unstructured":"Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Jackson EN, et al. The precivityad test: accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin Chim Acta. 2021;519:267\u201375. https:\/\/doi.org\/10.1016\/j.cca.2021.05.011.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"390_CR14","doi-asserted-by":"publisher","first-page":"e12131","DOI":"10.1002\/dad2.12131","volume":"13","author":"A Keshavan","year":"2021","unstructured":"Keshavan A, Wellington H, Chen Z, Khatun A, Chapman M, Hart M, et al. Concordance of CSF measures of Alzheimer\u2019s pathology with amyloid PET status in a preclinical cohort: a comparison of lumipulse and established immunoassays. Alzheimers Dement. 2021;13(1):e12131. https:\/\/doi.org\/10.1002\/dad2.12131.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"390_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13195-018-0448-x","volume":"10","author":"H Shahpasand-Kroner","year":"2018","unstructured":"Shahpasand-Kroner H, Klafki HW, Bauer C, Schuchhardt J, Huttenrauch M, Stazi M, et al. A two-step immunoassay for the simultaneous assessment of Abeta38, Abeta40 and Abeta42 in human blood plasma supports the Abeta42\/Abeta40 ratio as a promising biomarker candidate of Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):121. https:\/\/doi.org\/10.1186\/s13195-018-0448-x.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"390_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","volume":"5","author":"AE Roher","year":"2009","unstructured":"Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease. Alzheimers Dement. 2009;5(1):18\u201329. https:\/\/doi.org\/10.1016\/j.jalz.2008.10.004.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"390_CR17","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/j.1471-4159.1993.tb09841.x","volume":"61","author":"C Vigo-Pelfrey","year":"1993","unstructured":"Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 1993;61(5):1965\u20138. https:\/\/doi.org\/10.1111\/j.1471-4159.1993.tb09841.x.","journal-title":"J Neurochem"},{"issue":"4","key":"390_CR18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/pr050475v","volume":"5","author":"E Portelius","year":"2006","unstructured":"Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5(4):1010\u20136. https:\/\/doi.org\/10.1021\/pr050475v.","journal-title":"J Proteome Res"},{"issue":"3","key":"390_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neulet.2006.09.044","volume":"409","author":"E Portelius","year":"2006","unstructured":"Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, et al. An Alzheimer\u2019s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett. 2006;409(3):215\u20139. https:\/\/doi.org\/10.1016\/j.neulet.2006.09.044.","journal-title":"Neurosci Lett"},{"issue":"11","key":"390_CR20","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1021\/pr0703627","volume":"6","author":"E Portelius","year":"2007","unstructured":"Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6(11):4433\u20139. https:\/\/doi.org\/10.1021\/pr0703627.","journal-title":"J Proteome Res"},{"issue":"1","key":"390_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbadis.2017.07.005","volume":"1864","author":"E Cabrera","year":"2018","unstructured":"Cabrera E, Mathews P, Mezhericher E, Beach TG, Deng J, Neubert TA, et al. Abeta truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis. 2018;1864(1):208\u201325. https:\/\/doi.org\/10.1016\/j.bbadis.2017.07.005.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"390_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bfgp\/elm010","volume":"6","author":"V Gelfanova","year":"2007","unstructured":"Gelfanova V, Higgs RE, Dean RA, Holtzman DM, Farlow MR, Siemers ER, et al. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. Brief Funct Genomic Proteomic. 2007;6(2):149\u201358. https:\/\/doi.org\/10.1093\/bfgp\/elm010.","journal-title":"Brief Funct Genomic Proteomic"},{"key":"390_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fnagi.2016.00223","volume":"8","author":"FL McIntee","year":"2016","unstructured":"McIntee FL, Giannoni P, Blais S, Sommer G, Neubert TA, Rostagno A, et al. In vivo differential brain clearance and catabolism of monomeric and oligomeric Alzheimer\u2019s abeta protein. Front Aging Neurosci. 2016;8:223. https:\/\/doi.org\/10.3389\/fnagi.2016.00223.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"390_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/jnc.15571","volume":"160","author":"HW Klafki","year":"2022","unstructured":"Klafki HW, Wirths O, Mollenhauer B, Liepold T, Rieper P, Esselmann H, et al. Detection and quantification of abeta-3-40 (APP669-711) in cerebrospinal fluid. J Neurochem. 2022;160(5):578\u201389. https:\/\/doi.org\/10.1111\/jnc.15571.","journal-title":"J Neurochem"},{"issue":"20","key":"390_CR25","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1002\/pmic.200700311","volume":"7","author":"JM Maler","year":"2007","unstructured":"Maler JM, Klafki HW, Paul S, Spitzer P, Groemer TW, Henkel AW, et al. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel abeta species. Proteomics. 2007;7(20):3815\u201320. https:\/\/doi.org\/10.1002\/pmic.200700311.","journal-title":"Proteomics"},{"issue":"3","key":"390_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2183\/pjab.90.104","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Yamamoto R, Sato TA, Tanaka K. Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(3):104\u201317. https:\/\/doi.org\/10.2183\/pjab.90.104.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"1","key":"390_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13195-022-01071-y","volume":"14","author":"HW Klafki","year":"2022","unstructured":"Klafki HW, Vogelgsang J, Manuilova E, Bauer C, Jethwa A, Esselmann H, et al. Diagnostic performance of automated plasma amyloid-beta assays combined with pre-analytical immunoprecipitation. Alzheimers Res Ther. 2022;14(1):127. https:\/\/doi.org\/10.1186\/s13195-022-01071-y.","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"390_CR28","doi-asserted-by":"publisher","first-page":"8142","DOI":"10.1021\/ac401055y","volume":"85","author":"U Haussmann","year":"2013","unstructured":"Haussmann U, Jahn O, Linning P, Janssen C, Liepold T, Portelius E, et al. Analysis of amino-terminal variants of amyloid-beta peptides by capillary isoelectric focusing immunoassay. Anal Chem. 2013;85(17):8142\u20139. https:\/\/doi.org\/10.1021\/ac401055y.","journal-title":"Anal Chem"},{"issue":"7","key":"390_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/nan.12637","volume":"46","author":"S Zampar","year":"2020","unstructured":"Zampar S, Klafki HW, Sritharen K, Bayer TA, Wiltfang J, Rostagno A, et al. N-terminal heterogeneity of parenchymal and vascular amyloid-beta deposits in Alzheimer\u2019s disease. Neuropathol Appl Neurobiol. 2020;46(7):673\u201385. https:\/\/doi.org\/10.1111\/nan.12637.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"25","key":"390_CR30","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1002\/chem.201600892","volume":"22","author":"I Beyer","year":"2016","unstructured":"Beyer I, Rezaei-Ghaleh N, Klafki HW, Jahn O, Haussmann U, Wiltfang J, et al. Solid-phase synthesis and characterization of n-terminally elongated abeta-3-x -peptides. Chemistry. 2016;22(25):8685\u201393. https:\/\/doi.org\/10.1002\/chem.201600892.","journal-title":"Chemistry"},{"issue":"18","key":"390_CR31","doi-asserted-by":"publisher","first-page":"6564","DOI":"10.3390\/ijms21186564","volume":"21","author":"HW Klafki","year":"2020","unstructured":"Klafki HW, Rieper P, Matzen A, Zampar S, Wirths O, Vogelgsang J, et al. Development and technical validation of an immunoassay for the detection of APP669-711 (Abeta-3-40) in biological samples. Int J Mol Sci. 2020;21(18):6564. https:\/\/doi.org\/10.3390\/ijms21186564.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"390_CR32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3233\/JAD-160398","volume":"54","author":"HW Klafki","year":"2016","unstructured":"Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, et al. Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-beta peptides in human cerebrospinal fluid and application to a clinical cohort. J Alzheimers Dis. 2016;54(2):691\u2013705. https:\/\/doi.org\/10.3233\/JAD-160398.","journal-title":"J Alzheimers Dis"},{"issue":"382","key":"390_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/01621459.1983.10477973","volume":"78","author":"B Efron","year":"1983","unstructured":"Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc. 1983;78(382):316\u201331.","journal-title":"J Am Stat Assoc"},{"issue":"9","key":"390_CR34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2183\/pjab.90.353","volume":"90","author":"N Kaneko","year":"2014","unstructured":"Kaneko N, Nakamura A, Washimi Y, Kato T, Sakurai T, Arahata Y, et al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(9):353\u201364.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"7691","key":"390_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354. https:\/\/doi.org\/10.1038\/nature25456.","journal-title":"Nature"},{"issue":"4","key":"390_CR36","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1073\/pnas.94.4.1550","volume":"94","author":"K Johnson-Wood","year":"1997","unstructured":"Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, et al. Amyloid precursor protein processing and a beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA. 1997;94(4):1550\u20135. https:\/\/doi.org\/10.1073\/pnas.94.4.1550.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"390_CR37","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ana.24270","volume":"76","author":"KF Roberts","year":"2014","unstructured":"Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, et al. Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol. 2014;76(6):837\u201344. https:\/\/doi.org\/10.1002\/ana.24270.","journal-title":"Ann Neurol"},{"issue":"1","key":"390_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s42003-022-03037-0","volume":"5","author":"DL Elbert","year":"2022","unstructured":"Elbert DL, Patterson BW, Lucey BP, Benzinger TLS, Bateman RJ. Importance of CSF-based abeta clearance with age in humans increases with declining efficacy of blood-brain barrier\/proteolytic pathways. Commun Biol. 2022;5(1):98. https:\/\/doi.org\/10.1038\/s42003-022-03037-0.","journal-title":"Commun Biol"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-022-00390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T19:03:00Z","timestamp":1670180580000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-022-00390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s12987-022-00390-4","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of the University of Goettingen (9\/2\/16) has approved the collection and archiving of biological samples and clinical data in strictly pseudonymous form in a local biobank and their use in biomarker research. From all participants or their legal representatives written informed consent was obtained prior to the inclusion in the biobank. All procedures involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.W. has been an honorary speaker for Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, and has been a member of the advisory boards of Abbott, Biogen, Boehringer Ingelheim, Lilly, MSD Sharp & Dohme, and Roche Pharma and receives fees as a consultant for Immungenetics and Roboscreen. J.W. holds the following patents: PCT\/EP 2011 001724 and PCT\/EP 2015 052945. J.S. and C.B. are employees of Microdiscovery GmbH, Berlin, Germany. H.-W.K., B.M., O.J., O.W. and H.E. declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}